Roivant Sciences Ltd. ROIV
41.85 USD +0.66 (+1.60%)
At closeNov 12, 2026, 5:04 AM EST
41.50 -0.35 -0.84%
Pre-market · Nov 12, 5:04 AM ET
40.92 Day range 42.24
19.96 52-week range 42.50
- YTD
- +92.86%
- 1 year
- +100.24%
News
seekingalpha.com Don't Fight The Momentum: Roivant Has Big Expectations, But Real Pipeline Momentum Roivant Sciences Ltd. remains a Buy as its diversified "-vant" model delivers multiple blockbuster pipeline opportunities and robust cash reserves. Immunovant's IMVT-1402 shows superior efficacy in…
globenewswire.com Priovant Announces Publication of Phase 2 BEACON Results for Brepocitinib in Cutaneous Sarcoidosis in JAMA Dermatology DURHAM, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics today announced the publication in JAMA Dermatology of results from the Phase 2 portion of the BEACON study, a randomized,…
benzinga.com Nvidia To $300? Here Are 10 Top Analyst Forecasts For Tuesday Analysts adjusted targets: RIOT upgraded to Buy; WIX downgraded to Underperform; targets also changed for MNDY, ONTO, ROIV, FERG and NVDA.
benzinga.com HC Wainwright & Co. Maintains Buy on Roivant Sciences, Raises Price Target to $48 HC Wainwright & Co. analyst Douglas Tsao maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $47 to $48.
defenseworld.net Roivant Sciences Ltd. $ROIV Stock: CenterBook Partners LP Cuts Position CenterBook Partners LP decreased its stake in Roivant Sciences Ltd. (NASDAQ: ROIV) by 35.6% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange…
seekingalpha.com Roivant Sciences Ltd. (ROIV) Q2 2026 Earnings Call Transcript Roivant Sciences Ltd. ( ROIV ) Q2 2026 Earnings Call November 9, 2026 8:00 AM EST Company Participants Stephanie Lee Griffin - Chief Operating Officer of Roivant Platforms Matthew Gline - CEO &…
marketbeat.com Roivant Sciences Q2 Earnings Call Highlights Roivant Sciences NASDAQ: ROIV reported $31 million in net revenue from the initial launch of LISRAYA and said an experimental rheumatoid arthritis treatment met its primary endpoint in a randomized…
zacks.com Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Tops Revenue Estimates Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.41.
benzinga.com Roivant Sciences Q2 2027 Earnings Call Transcript Roivant Sciences (NASDAQ:ROIV) reported second-quarter financial results on Monday. The transcript from the company’s second-quarter earnings call has been provided below.This transcript is brought…
globenewswire.com Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended September 30, 2026 IMVT-1402 600 mg met the primary endpoint of ACR20 response at Week 28 (92.5% vs. 75.6% placebo, p=0.0139) in Period 2 (randomized withdrawal design following open-label lead-in) of the potentially…
globenewswire.com Roivant Reports Financial Results for the Second Quarter Ended September 30, 2026, and Provides Business Update LISRAYA™ (brepocitinib) generated net product revenue of $31.0 million in its first 5 weeks of launch following FDA approval in August 2026 IMVT-1402 600 mg met the primary endpoint of ACR20 response…
benzinga.com KKR, Constellation Energy On Deck Monday As Private Credit, Power Face Test KKR headlines Monday’s reports, with investors weighing whether fundraising momentum can offset a sharp year-to-date stock decline. Constellation Energy, Barrick Mining, Ferguson Enterprises and ORIX…
defenseworld.net Roivant Sciences (NASDAQ:ROIV) Stock: Insider Eric Venker Sells 200,000 Shares Roivant Sciences Ltd. (NASDAQ: ROIV - Get Free Report) CEO Eric Venker sold 200,000 shares of the firm's stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of…
defenseworld.net Roivant Sciences (NASDAQ:ROIV) Stock: Insider Eric Venker Sells 200,000 Shares Roivant Sciences Ltd. (NASDAQ: ROIV - Get Free Report) CEO Eric Venker sold 200,000 shares of the firm's stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of…
benzinga.com Here’s How Much You Would Have Made Owning Roivant Sciences Stock In The Last 5 Years Roivant Sciences (NASDAQ:ROIV) has outperformed the market over the past 5 years by 26.08% on an annualized basis producing an average annual return of 35.57%. Currently, Roivant Sciences has a…
benzinga.com Citigroup Maintains Buy on Roivant Sciences, Raises Price Target to $56 Citigroup analyst Samantha Semenkow maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $46 to $56.
benzinga.com If You Invested $100 In Roivant Sciences Stock 5 Years Ago, You Would Have This Much Today Roivant Sciences (NASDAQ:ROIV) has outperformed the market over the past 5 years by 26.86% on an annualized basis producing an average annual return of 37.68%. Currently, Roivant Sciences has a…
benzinga.com Why Is Roivant Sciences Stock Surging Wednesday? Roivant (ROIV) shares jump as Phase 3 CLARITY trials show brepocitinib effectively treats noninfectious uveitis & reduces steroid reliance.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Pharvaris (NASDAQ:PHVS) stock moved upwards by 19.4% to $36.9 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.0 billion. CalciMedica (NASDAQ:CALC)…
benzinga.com Here’s How Much You Would Have Made Owning Roivant Sciences Stock In The Last 5 Years Roivant Sciences (NASDAQ:ROIV) has outperformed the market over the past 5 years by 30.08% on an annualized basis producing an average annual return of 41.86%. Currently, Roivant Sciences has a…
benzinga.com This Insmed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday Analysts downgraded UWMC, ACT, ROIV, INSM; ACT’s target fell to $44.